Clinical Trials Logo
  1. Home
  2. Bladder Pain Syndrome
  3. NCT02981459

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

Bladder Pain Syndrome Clinical Trial

Official title:
Pilot Study: Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women, an Open Label Study With Dose Escalation

Clinical Trial Summary

The specific purpose of this study is to provide objective data in prospective open label design (n=40) to support the use of Mirabegron as a treatment for pain related urinary frequency and urgency. Women with bladder pain have a poor response to traditional anticholinergic therapy for their symptoms of frequency and urgency.

Clinical Trial Description

Hypothesis: Mirabegron is effective in reducing symptoms in women with pain related urinary frequency and urgency. Specific Aims: 1. To measure the efficacy of Mirabegron in the treatment of frequency and urgency, using voiding diaries. 2. To measure the number of patients with a 50% or greater reduction in frequency and urgency, using voiding diaries. 3. To measure the number of patients with a 50% or greater reduction in bladder pain as measured in the O'Leary-Sant (OLS) IC symptom and problem, and the Lowell Parsons Pelvic Pain and Urgency/Frequency (PUF) patient symptom scale. Intervention/Project goal: Treatment with Mirabegron 25mg for 4 weeks with an option for dose escalation to 50mg. Duration of study 12 weeks. Inclusion criteria: Women between the ages of 18 and 89 with complaints of pain related urinary frequency are eligible to participate in the study. Exclusion criteria: Patients will be excluded from the study if they have: 1. Severe Liver disease, Child-Pugh class c 2. Severe Kidney disease, GFR<30 3. Elevated blood pressure > 160/95 (in package insert bp >180/110) 4. Urinary retention 5. Pregnant, will become pregnant, or are nursing 6. History of recurrent urinary tract infection 7. Tachycardia: pulse > 100 8. Presently on study drug mirabegron; patient must be willing to participate in a 30 day washout period to be eligible for inclusion 9. Medications - metoprolol, desipramine, digoxin, propafenone, thioridazine, flecainide, warfarin ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02981459
Study type Interventional
Source State University of New York at Buffalo
Contact
Status Withdrawn
Phase Phase 4
Start date December 8, 2017
Completion date June 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT04313972 - IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone Phase 4
Completed NCT03282318 - A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Phase 2
Terminated NCT02591199 - Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Completed NCT04401176 - Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Completed NCT04001244 - Translational Research in Pelvic Pain
Suspended NCT04450316 - Low-dose Naltrexone for Bladder Pain Syndrome Phase 2
Completed NCT04010513 - Hypnosis for Bladder Pain Syndrome N/A
Recruiting NCT05518864 - GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis (GETSBI Study) Phase 4
Active, not recruiting NCT05414305 - The Female Microbiome in Patients Undergoing Bladder Instillation Therapy Phase 2
Withdrawn NCT03027076 - Microbiome of Urologic Chronic Pelvic Pain Syndrome N/A
Terminated NCT01879930 - Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study Phase 4
Recruiting NCT05155384 - Biopsychosocial and Conventional Approach in Bladder Pain Syndrome N/A
Recruiting NCT05737121 - Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS Phase 2
Not yet recruiting NCT04734106 - Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis Early Phase 1
Recruiting NCT05699551 - Supervised Exercise as a Therapeutic Strategy for Interstitial Cystitis/Bladder Pain Syndrome N/A
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Completed NCT04821882 - Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis N/A
Completed NCT04208087 - PK and Safety of SI-722 in IC/BPS Phase 1/Phase 2
Recruiting NCT05740007 - Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Enrolling by invitation NCT06212661 - Migraine Medication Effects on Urinary Symptoms